Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism
Open Access
- 1 March 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 30 (3), 382-387
- https://doi.org/10.1161/atvbaha.110.203117
Abstract
Venous thromboembolism remains a frequent cause of vascular death. Despite advances in anticoagulant drug development, unmet needs remain, including limited treatment options for patients with severe renal impairment and the inability to fully reverse the effects of anticoagulants approved or in late-stage development. Because coagulation factor IXa plays a pivotal role in tissue factor-mediated thrombin generation, it represents an attractive target for anticoagulant development. This article discusses the rationale for factor IXa as an anticoagulant target and the potential role in venous thromboembolism prevention or management of the 2 factor IXa inhibitors that have undergone testing in phase 1 or 2 trials: TTP889, an oral, small-molecule compound, and RB006, an aptamer-based compound, the intravenous and subcutaneous formulations of which are the anticoagulant components of the REG1 and REG2 anticoagulation systems, respectively.Keywords
This publication has 42 references indexed in Scilit:
- Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In VivoCell, 2009
- The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosisBlood, 2008
- Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery DiseaseCirculation, 2008
- A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitorJournal of Thrombosis and Haemostasis, 2008
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory studyJournal of Thrombosis and Haemostasis, 2007
- First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer TechnologyCirculation, 2006
- The worcester venous thromboembolism studyJournal of General Internal Medicine, 2006
- Oral Anticoagulants in DevelopmentDrugs, 2006
- The Significance of Circulating Factor IXa in BloodPublished by Elsevier BV ,2004